Switch to:
Also traded in: Japan
» Details

Insider Trades

Latest Guru Trades with OPHLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:KYKOF, OTCPK:DSNKY, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:CHGCY, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF, OTCPK:HAWPF, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:ASMB, NAS:RMTI, NAS:NBRV, NAS:ZGNX, OTCPK:AGYTF, NAS:OASM, NAS:ALIM » details
Traded in other countries:4528.Japan,
ONO Pharmaceutical Co., Ltd., along with its subsidiaries is engaged in research & development, manufacturing and selling of medical and general pharmaceutical products.

Ono Pharmaceutical Co Ltd was incorporated in Japan on July 4, 1947. The Company along with its subsidiaries is engaged in research & development, manufacturing and selling of medical and general pharmaceutical products. Its product portfolio includes GLACTIV Tablets for the Treatment of Type 2 Diabetes; RECALBON Tablets for the Treatment of Osteoporosis; EMEND Capsules / PROEMEND for Intravenous Injection for the Treatment of Chemotherapy-induced Nausea and Vomiting, STAYBLA Tablets for the Treatment of Overactive Bladder; RIVASTACH Patch for the Treatment of Alzheimer's Disease; ORENCIA for Subcutaneous Injection for the Treatment of Rheumatoid Arthritis; FORXIGA Tablets for the Treatment of Type 2 Diabetes; OPALMON Tablets for the Treatment of Peripheral Circulatory Disorder; ONOACT for Intravenous Infusion for the Treatment of Tachyarrhythmia Intra-operative or Post-operative, or Tachyarrhythmia in Left Ventricular Dysfunction; and ELASPOL for Injection for the Treatment of Acute Lung Injury Associated with Systemic Inflammatory Response Syndrome. The Company has operations in geographical areas including; Japan, Europe, and Asia.

Ratios

vs
industry
vs
history
P/E(ttm) 47.53
OPHLY's P/E(ttm) is ranked lower than
74% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. OPHLY: 47.53 )
Ranked among companies with meaningful P/E(ttm) only.
OPHLY' s P/E(ttm) Range Over the Past 10 Years
Min: 14.12  Med: 29.53 Max: 574.64
Current: 47.53
14.12
574.64
PE(NRI) 47.53
OPHLY's PE(NRI) is ranked lower than
73% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. OPHLY: 47.53 )
Ranked among companies with meaningful PE(NRI) only.
OPHLY' s PE(NRI) Range Over the Past 10 Years
Min: 14.12  Med: 29.53 Max: 574.29
Current: 47.53
14.12
574.29
Price/Owner Earnings (ttm) 69.98
OPHLY's Price/Owner Earnings (ttm) is ranked lower than
78% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. OPHLY: 69.98 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
OPHLY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.9  Med: 69.26 Max: 2425.5
Current: 69.98
18.9
2425.5
P/B 2.67
OPHLY's P/B is ranked higher than
56% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. OPHLY: 2.67 )
Ranked among companies with meaningful P/B only.
OPHLY' s P/B Range Over the Past 10 Years
Min: 0.94  Med: 1.38 Max: 5.84
Current: 2.67
0.94
5.84
P/S 6.78
OPHLY's P/S is ranked lower than
72% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. OPHLY: 6.78 )
Ranked among companies with meaningful P/S only.
OPHLY' s P/S Range Over the Past 10 Years
Min: 2.78  Med: 4.81 Max: 99.18
Current: 6.78
2.78
99.18
PFCF 71.37
OPHLY's PFCF is ranked lower than
82% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. OPHLY: 71.37 )
Ranked among companies with meaningful PFCF only.
OPHLY' s PFCF Range Over the Past 10 Years
Min: 14.89  Med: 34.42 Max: 346.12
Current: 71.37
14.89
346.12
POCF 34.75
OPHLY's POCF is ranked lower than
76% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. OPHLY: 34.75 )
Ranked among companies with meaningful POCF only.
OPHLY' s POCF Range Over the Past 10 Years
Min: 14.18  Med: 38.5 Max: 406.27
Current: 34.75
14.18
406.27
EV-to-EBIT 18.62
OPHLY's EV-to-EBIT is ranked higher than
55% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. OPHLY: 18.62 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.9  Med: 16.05 Max: 405.7
Current: 18.62
6.9
405.7
EV-to-EBITDA 16.75
OPHLY's EV-to-EBITDA is ranked higher than
51% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. OPHLY: 16.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.5  Med: 15.1 Max: 358.4
Current: 16.75
6.5
358.4
Current Ratio 3.94
OPHLY's Current Ratio is ranked higher than
68% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. OPHLY: 3.94 )
Ranked among companies with meaningful Current Ratio only.
OPHLY' s Current Ratio Range Over the Past 10 Years
Min: 3.94  Med: 7.2 Max: 9.15
Current: 3.94
3.94
9.15
Quick Ratio 3.54
OPHLY's Quick Ratio is ranked higher than
72% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. OPHLY: 3.54 )
Ranked among companies with meaningful Quick Ratio only.
OPHLY' s Quick Ratio Range Over the Past 10 Years
Min: 3.5  Med: 6.51 Max: 8.47
Current: 3.54
3.5
8.47
Days Inventory 142.62
OPHLY's Days Inventory is ranked lower than
64% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. OPHLY: 142.62 )
Ranked among companies with meaningful Days Inventory only.
OPHLY' s Days Inventory Range Over the Past 10 Years
Min: 142.62  Med: 209.74 Max: 273.09
Current: 142.62
142.62
273.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.58
OPHLY's Dividend Yield is ranked higher than
96% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. OPHLY: 1.58 )
Ranked among companies with meaningful Dividend Yield only.
OPHLY' s Dividend Yield Range Over the Past 10 Years
Min: 0.83  Med: 2.95 Max: 5.3
Current: 1.58
0.83
5.3
Dividend Payout 0.70
OPHLY's Dividend Payout is ranked lower than
79% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. OPHLY: 0.70 )
Ranked among companies with meaningful Dividend Payout only.
OPHLY' s Dividend Payout Range Over the Past 10 Years
Min: 0.35  Med: 0.89 Max: 11.46
Current: 0.7
0.35
11.46
Dividend Growth (3y) 44.20
OPHLY's Dividend Growth (3y) is ranked higher than
91% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. OPHLY: 44.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
OPHLY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
Forward Dividend Yield 1.56
OPHLY's Forward Dividend Yield is ranked higher than
53% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. OPHLY: 1.56 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.42
OPHLY's Yield on cost (5-Year) is ranked higher than
95% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. OPHLY: 3.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
OPHLY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.82  Med: 6.47 Max: 11.62
Current: 3.42
1.82
11.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.37
OPHLY's Price/Net Cash is ranked lower than
76% of the 250 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.84 vs. OPHLY: 27.37 )
Ranked among companies with meaningful Price/Net Cash only.
OPHLY' s Price/Net Cash Range Over the Past 10 Years
Min: 3.78  Med: 6.61 Max: 44.25
Current: 27.37
3.78
44.25
Price/Net Current Asset Value 8.03
OPHLY's Price/Net Current Asset Value is ranked lower than
52% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OPHLY: 8.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPHLY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 3.68 Max: 16.35
Current: 8.03
2.39
16.35
Price/Tangible Book 2.91
OPHLY's Price/Tangible Book is ranked higher than
59% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. OPHLY: 2.91 )
Ranked among companies with meaningful Price/Tangible Book only.
OPHLY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.99  Med: 1.42 Max: 5.83
Current: 2.91
0.99
5.83
Price/Projected FCF 2.68
OPHLY's Price/Projected FCF is ranked higher than
50% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. OPHLY: 2.68 )
Ranked among companies with meaningful Price/Projected FCF only.
OPHLY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.1  Med: 2.7 Max: 26.66
Current: 2.68
1.1
26.66
Price/Median PS Value 1.41
OPHLY's Price/Median PS Value is ranked lower than
66% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. OPHLY: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHLY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.62  Med: 1.05 Max: 18.52
Current: 1.41
0.62
18.52
Price/Graham Number 2.48
OPHLY's Price/Graham Number is ranked lower than
55% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. OPHLY: 2.48 )
Ranked among companies with meaningful Price/Graham Number only.
OPHLY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.42  Med: 1.32 Max: 11.44
Current: 2.48
0.42
11.44
Earnings Yield (Greenblatt) (%) 5.35
OPHLY's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. OPHLY: 5.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHLY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 6.2 Max: 14.4
Current: 5.35
0.2
14.4
Forward Rate of Return (Yacktman) (%) -0.17
OPHLY's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. OPHLY: -0.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OPHLY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.3  Med: -5.4 Max: 29.1
Current: -0.17
-14.3
29.1

More Statistics

Revenue (TTM) (Mil) $2,174
EPS (TTM) $ 0.17
Beta0.17
Short Percentage of Float0.00%
52-Week Range $6.57 - 21.45
Shares Outstanding (Mil)1,590.28
» More Articles for OPHLY

Headlines

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary Oct 26 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report May 13 2016 

More From Other Websites
Ono Pharmaceutical Co., Ltd. :OPHLY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 3,... Feb 03 2017
ETFs with exposure to Ono Pharmaceutical Co., Ltd. : January 24, 2017 Jan 24 2017
Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following... Jan 24 2017
ETFs with exposure to Ono Pharmaceutical Co., Ltd. : December 2, 2016 Dec 02 2016
Ono Pharmaceutical Co., Ltd. :OPHLY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 8,... Nov 08 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : October 18, 2016 Oct 18 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : October 7, 2016 Oct 07 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : August 24, 2016 Aug 24 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : August 11, 2016 Aug 11 2016
Ono Pharmaceutical Co., Ltd. :OPHLY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 5, 2016 Aug 05 2016
Ono Pharmaceutical Co., Ltd. :OPHLY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : July 25, 2016 Jul 25 2016
ETF’s with exposure to Ono Pharmaceutical Co., Ltd. : June 21, 2016 Jun 21 2016
Ono Pharmaceutical Co., Ltd. :OPHLY-US: Earnings Analysis: Q4, 2016 By the Numbers May 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK